Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.
Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.
Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time.
Conclusion: Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.
Keywords: antidepressant; antipsychotic; bipolar disorder; generalized anxiety disorder; major depressive disorder; mood stabilizer; pharmacogenetics; selective serotonin reuptake inhibitors; tricyclic antidepressants.